296 related articles for article (PubMed ID: 27072669)
21. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
Foley JE; Bhosekar V; Kawamori R
Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
[TBL] [Abstract][Full Text] [Related]
22. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Scheen AJ
Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
[TBL] [Abstract][Full Text] [Related]
23. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.
Lyu X; Zhu X; Zhao B; Du L; Chen D; Wang C; Liu G; Ran X
Sci Rep; 2017 Mar; 7():44865. PubMed ID: 28322294
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
[TBL] [Abstract][Full Text] [Related]
26. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS
Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Triple Therapy with SGLT-2 Inhibitor, DPP-4 Inhibitor, and Metformin in Type 2 Diabetes: A Meta-Analysis.
Li M; Wang S; Wang X
Altern Ther Health Med; 2023 Jul; 29(5):320-326. PubMed ID: 37171944
[TBL] [Abstract][Full Text] [Related]
29. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
[TBL] [Abstract][Full Text] [Related]
30. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.
Kim YG; Hahn S; Oh TJ; Kwak SH; Park KS; Cho YM
Diabetologia; 2013 Apr; 56(4):696-708. PubMed ID: 23344728
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis.
Guo W; Nie L; Wang XR; Xu ML; Yang WJ; Gao XY; Cai XL; Ji LN
Chin Med J (Engl); 2018 Jul; 131(13):1605-1612. PubMed ID: 29941715
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
35. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
36. The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
Velija-Asimi Z; Izetbegovic S; Karamehic J; Coric J; Panjeta M; Macic-Dzankovic A; Djelilovic-Vranic J; Dizdarevic-Bostandzic A
Med Arch; 2013; 67(5):365-7. PubMed ID: 24601174
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
[TBL] [Abstract][Full Text] [Related]
38. Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes.
Bae J; Kim YE; Lee M; Lee YH; Lee BW; Cha BS; Kang ES
Yonsei Med J; 2022 Jun; 63(6):539-544. PubMed ID: 35619577
[TBL] [Abstract][Full Text] [Related]
39. Metformin plus a low hypoglycemic risk antidiabetic drug vs. metformin monotherapy for untreated type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Hung WT; Chen YJ; Cheng CY; Ovbiagele B; Lee M; Hsu CY
Diabetes Res Clin Pract; 2022 Jul; 189():109937. PubMed ID: 35662614
[TBL] [Abstract][Full Text] [Related]
40. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Kawalec P; Mikrut A; Ĺopuch S
Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]